Molecular Partners AG

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Senior Management and invited guests will host a virtual Oncology R&D Day.

Molecular Partners to Host Oncology Day (Virtual)

Novartis

Molecular Partners AG (NASDAQ: MOLN) entered into a license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies (DARPin-RLTs). According to the license agreement, Novartis will pay $20 million upfront to Molecular Partners.

Molecular Partners Inks License Deal With Novartis For $580M

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:

Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a series of events in December 2021 that will highlight various aspects of its DARPin cancer therapeutic portfolio. These events include a presentation at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Congress, focused on the clinical-stage fibroblast activation protein (FAP)-targeted CD40 activator candidate, MP0317; a presentation at the American Society of Hematology (ASH) Annual Meeting, focused on MP0533, the company's acute myeloid leukemia (AML) candidate, designed to simultaneously engage CD3 on T cells and target three tumor associated antigens (TAAs); and a comprehensive review of the company's cancer portfolio and its research & development strategy at a virtual Oncology Day to be held at 8:30 am ET on December 15, 2021.

Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in December

Molecular Partners AG (NASDAQ: MOLN) announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients and additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza (ESWI) Conference. The single-arm Phase 2a study enrolled 12 patients with mild to moderate COVID-19 symptoms.

Molecular Partners' Ensovibep Shows Early Safety Profile In COVID-19

ZURICH-SCHLIEREN, Switzerland and CONCORD Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients as well as additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza (ESWI) Conference. The single arm Phase 2a study enrolled 12 patients, all of whom were confirmed as positive for COVID-19 with mild to moderate symptoms. The single center study was designed to evaluate dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep. The results were presented by study investigator Dr. Johan van der Plas from the Centre for Human Drug Research (CHDR), Leiden, the Netherlands;

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a research collaboration with University of Bern, to advance the development of the Company's wholly owned acute myeloid leukemia (AML) candidate, MP0533, into the clinic. MP0533 is a DARPin designed to engage CD3 on T cells and target AML cells by the tumor associated antigens (TAAs) CD33, CD123 and CD70. The collaboration aims to leverage Molecular Partners' proprietary DARPin technology and the University of Bern group's expertise in AML, and specifically in leukemic stem cells (LSC), a hard-to-target cancer progenitor cell population.

Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML

ImmunoGen

Wall Street is having a bad day, but shareholders in these companies are celebrating.

These 2 Nasdaq Biotechs Are Bucking the Market Downtrend

Molecular Partners AG (NASDAQ: MOLN) said that its ensovibep, a tri-specific antiviral targeting the spike protein of SARS-CoV-2, maintains full potency against the individual positions of relevance to ensovibep that are mutated in the Omicron variant. Ensovibep has been consistently tested in vitro against all existing and potential variants of concerns.

Molecular Partners Says Its COVID-19 Antiviral Still Effective Against Positions Mutated In Omicron

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today issued a statement regarding the recently identified SARS-CoV-2 variant, termed Omicron (B.1.1.529)1. The Omicron strain contains 32 new mutations compared to the wild-type strain originally identified in Wuhan, China. Based on previous studies, ensovibep, a tri-specific antiviral targeting the spike protein of SARS-CoV-2, maintains full potency against the individual positions of relevance to ensovibep that are mutated in the Omicron variant.

Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Nov 30, 2021, at 8:00 AM EST.

Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference

Molecular Partners AG (NASDAQ: MOLN) has announced that a planned futility analysis of ensovibep in the Phase 3 ACTIV-3 study has not met the thresholds required to continue enrollment of hospitalized adults with COVID-19. The independent Data and Safety Monitoring Board (DSMB) recommends discontinuing recruitment in the ensovibep arm of the ACTIV-3 study conducted by the National Institutes of Health (NIH).

See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that a planned futility analysis of ensovibep in the ongoing ACTIV-3 clinical study (NCT04501978) has not met the thresholds required to continue enrollment of adults with COVID-19 in the hospitalized setting. This global Phase 3 ACTIV-3 platform study is being conducted by the National Institutes of Health (NIH) as part of its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is evaluating multiple therapies for COVID-19 to see what, if any, benefit can be seen over current standard of care. At the time of the analysis, 470 patients had been randomized in the ensovibep arm of the study. Ensovibep was observed to be generally safe and well tolerated with reported side effects consistent with standard of care.

Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:

Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum

ZURICH-SCHLIEREN, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the presentation of in vitro data describing the inhibition capabilities of ensovibep against COVID-19 variants of concern at the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) and World Health Organization (WHO) COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment conference, October 19-21, 2021. The results were selected for oral presentation. In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.

Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference

-- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3

Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021

AbbVie

AbbVie Inc (NYSE: ABBV) has terminated its license and collaboration agreement with Molecular Partners AG (NASDAQ: MOLN) for abicipar pegol for neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME).  As such, Molecular Partners will regain the development and commercial rights of abicipar on a worldwide basis.

AbbVie Returns Eye Drug Candidate To Molecular Partners

ZURICH-SCHLIEREN, Switzerland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today the receipt of notification from its partner, AbbVie Inc., regarding its termination of the license and collaboration agreement for the investigational drug abicipar pegol for the treatment of neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME). As such, Molecular Partners will regain the development and commercial rights of abicipar on a worldwide basis.

Molecular Partners to Regain Global Rights to Abicipar

Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of $50, implying an upside potential of more than 150%. The company and its partner Novartis AG (NYSE: NVS) recently shared preclinical data showing that ensovibep retains full potency and viral inhibition against all known COVID-19 variants in circulation, including the key Delta variants.

Cowen Initiates Coverage On Molecular Partners With Price Target Of $50

ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR

Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2

News for Molecular Partners AG Stock (MOLN)